Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221890

Enrollment

Unknown

Registered

2012-08-20

Start date

2012-08-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Cognitive Impairment due to Alzheimer's Disease or mild Alzheimer Disease

Interventions

investigational material(s) Generic name etc : LY2886721 INN of investigational material : Therapeutic category code : 119 Other agents affecting central nervous system Dosage and Administration for

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Presents gradual and progressive change in memory function reported by participant or partner over more than 6 months 2.Meets criteria for MCI due to AD or Mild AD based on Free and Cued Selective Reminding score with Immediate Recall (FCSRT-IR) of greater than or equal to 16 for free recall or greater than or equal to 40 for total recall 3.Clinical Dementia Rating Scale (CDR) score of 0.5 or 1, memory box score of less than or equal to 0.5 4.Mini Mental State Examination (MMSE) score of 20-30 5.florbetapir F18 scan positive for the presence of amyloid beta 6.Women must be postmenopausal

Exclusion criteria

Exclusion criteria:

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026